Evidence map›Paper›PMID 38568898›Full record

ArticlePloS one2024

Enhancing radioprotection: A chitosan-based chelating polymer is a versatile radioprotective agent for prophylactic and therapeutic interventions against radionuclide contamination.

Arthur Durand, Tatiana Borisova, François Lux, Jordyn A Howard, Augustin Tillement, Halyna Kuznietsova, Natalia Dziubenko, Vladimir Lysenko, Laurent David, Daphné Morel and 4 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
1.0field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 6 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 3 countries.

Arthur DurandMexBrain, Villeurbanne, France.
Tatiana BorisovaDepartment of Neurochemistry, Palladin Institute of Biochemistry National Academy of Sciences of Ukraine, Kyiv, Ukraine.
François LuxInstitute of Light and Matter, UMR 5306, University of Lyon 1-CNRS, University of Lyon 1, Villeurbanne Cedex, France.ORCID 0000-0003-1568-0240
Jordyn A HowardMexBrain, Villeurbanne, France.
Augustin TillementInstitute of Light and Matter, UMR 5306, University of Lyon 1-CNRS, University of Lyon 1, Villeurbanne Cedex, France.
Halyna KuznietsovaCorporation Science Park, Taras Shevchenko National University of Kyiv, Kyiv, Ukraine.
Natalia DziubenkoCorporation Science Park, Taras Shevchenko National University of Kyiv, Kyiv, Ukraine.ORCID 0000-0002-2998-4168
Vladimir LysenkoInstitute of Light and Matter, UMR 5306, University of Lyon 1-CNRS, University of Lyon 1, Villeurbanne Cedex, France.
Laurent DavidUniv Lyon, Université Claude Bernard Lyon 1, INSA de Lyon, Université Jean Monet, CNRS, UMR 5223 Ingénierie des Matériaux Polymères (IMP), Villeurbanne Cedex, France.ORCID 0000-0003-3632-8537
Daphné MorelDepartment of Radiotherapy, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
Ross BerbecoDepartment of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, Massachusetts, United States of America.
Serhiy KomisarenkoDepartment of Neurochemistry, Palladin Institute of Biochemistry National Academy of Sciences of Ukraine, Kyiv, Ukraine.
Olivier TillementInstitute of Light and Matter, UMR 5306, University of Lyon 1-CNRS, University of Lyon 1, Villeurbanne Cedex, France.
Eric DeutschUniversité Paris-Saclay, Gustave Roussy, INSERM, Radiothérapie Moléculaire et Innovation Thérapeutique, Villejuif, France.
Université Claude Bernard Lyon 1 · FRNational Academy of Sciences of Ukraine · UATaras Shevchenko National University of Kyiv · UABrigham and Women's Hospital · USInserm · FRUniversité Paris-Saclay · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To mitigate the risk of radioactive isotope dissemination, the development of preventative and curative measures is of particular interest. For mass treatment, the developed solution must be easily administered, preferably orally, with effective, nontoxic decorporating properties against a wide range of radioactive isotopes. Currently, most orally administered chelation therapy products are quickly absorbed into the blood circulation, where chelation of the radioactive isotope is a race against time due to the short circulation half-life of the therapeutic. This report presents an alternative therapeutic approach by using a functionalized chitosan (chitosan@DOTAGA) with chelating properties that remains within the gastrointestinal tract and is eliminated in feces, that can protect against ingested radioactive isotopes. The polymer shows important in vitro chelation properties towards different metallic cations of importance, including (Cs(I), Ir(III), Th(IV), Tl(I), Sr(II), U(VI) and Co(II)), at different pH (from 1 to 7) representing the different environments in the gastrointestinal tract. An in vivo proof of concept is presented on a rodent model of uranium contamination following an oral administration of Chitosan@DOTAGA. The polymer partially prevents the accumulation of uranium within the kidneys (providing a protective effect) and completely prevents its uptake by the spleen.

Indexed as

ChitosanRadiation-Protective AgentsUraniumChelating AgentsPolymersChelating AgentsChitosanPolymersRadiation-Protective AgentsUranium

Identifiers

PMID38568898
PMCPMC10990188
OpenAlexW4393867395

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.